Galapagos Shelves Ulcerative Colitis Program After PhII Failure
This article was originally published in Scrip
Danish firm Galapagos NV has dropped development of its GLPG1205 in ulcerative colitis after it failed a Phase IIa trial. The G-protein coupled receptor 84-targeting small molecule was not shown with statistical significance to be more efficacious than placebo in the company's ORIGIN study. Details of the trial results will be published later this year, the firm said.